karonudib
Small moleculeexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2017 (NCT03036228)
Timeline
2010s
- Jan 1, 2017
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
NUDT1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- karonudib
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04077307 | Phase 1 | Sep 27, 2019 | Karolinska Institute, Thomas Helleday Foundation |
| NCT03036228 | Phase 1 | Jan 1, 2017 | Thomas Helleday Foundation |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Thomas Helleday Foundation | Academic/Hospital | 2 | 2 | 1 | 2017 |
| Karolinska Institute | Academic/Hospital | 1 | 0 | 1 | 2019 |
2 organizations
Page 1 / 1